Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Sotagliflozin and DKA rates in people with type 1 diabetes

Type 1 diabetes – November 2020 digest

A pooled analysis of data from two phase 3 clinical trials evaluates the incidence of diabetic ketoacidosis in people with type 1 diabetes using sotagliflozin as an adjunct to insulin therapy.

Sotagliflozin is a dual inhibitor of sodium–glucose cotransporter (SGLT2) 1 and 2 that is licensed as an adjunctive therapy to insulin in people with type 1 diabetes in the EU. This pooled analysis of data from two phase 3 clinical trials evaluated the incidence of diabetic ketoacidosis (DKA) in a total of 1575 people with type 1 diabetes who were randomised 1:1:1 to adjuctive sotagliflozin 200 mg, 400 mg or placebo for 1 year.

A total of 191 ketosis events were identified, occurring in 9.7%, 13.9% and 2.7% in the sotagliflozin 200 mg, 400 mg and placebo groups, respectively. Most of these were reversed by the participants or clinicians with usual measures, leaving 98 events to be submitted for adjudication as per the study protocols. Of these, 37 events in 36 participants were adjudicated to be DKA, with all but one occurring in the sotagliflozin groups. The DKA incidence rate was 3.1, 4.2 and 0.2 events per 100 person-years for sotagliflozin 200 mg, 400 mg and placebo, respectively.

Blood glucose at the time of DKA was ≥13.9 mmol/L in 64% of cases. Nineteen events were related to insulin pump failure and 14 to intercurrent illness. DKA risk was higher in people on insulin pump therapy, those with a BMI <27 kg/m2 (in whom sotagliflozin is not licensed in the EU) and those who had reductions in insulin dose of ≥10–20% compared with baseline. DKA risk was lower in the second part of the study, after warnings of increased risk of euglycaemic DKA in users of SGLT2 inhibitors were published.

Peters AL, McGuire DK, Danne T et al (2020) Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the inTandem 1 and 2 studies. Diabetes Care 43: 2713–20. https://doi.org/10.2337/dc20-0924

Click here for all this month’s Digests.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.